Vanda is criticizing the FDA’s restrictions on information companies can provide regarding off-label use of approved ...

Future Pak—whose acquisition offer was rejected by Vanda Pharmaceuticals last summer—is offering to buy Theratechnologies for ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...

The HIV-focused biopharma has received its latest bid from CDMO Future Pak for a cool $255 million, but the drugmaker had to ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) ...

VNDA opened at $4.50 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.87 and a 12-month high of $6.75. The firm has a market capitalization of $262.42 million, a P/E ratio of -14.06 and ...

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug ...

Analysts' ratings for Vanda Pharmaceuticals VNDA over the last quarter vary from bullish to bearish, as provided by 5 analysts. Summarizing their recent assessments, the table below illustrates ...